{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T23:20:27Z","timestamp":1765322427671,"version":"3.46.0"},"reference-count":16,"publisher":"BMJ","issue":"6406","license":[{"start":{"date-parts":[[1983,12,3]],"date-time":"1983-12-03T00:00:00Z","timestamp":439257600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br Med J (Clin Res Ed)"],"published-print":{"date-parts":[[1983,12,3]]},"abstract":"<jats:p>An agonist analogue of luteinising hormone releasing hormone (buserelin) was successfully used to treat women with endometriosis. A dose of 200 micrograms administered intranasally thrice daily was found to be effective in five patients, in whom the endometriotic lesions resolved after six months' treatment. Failure occurred in a sixth patient, who received only 400 micrograms once daily. Anovulation was induced in all subjects together with suppression of menstruation after the first month of treatment. Symptoms of abdominal pain, dysmenorrhoea, and dyspareunia were relieved during treatment, and one previously infertile patient conceived within two months of stopping treatment. No side effects were reported with this dosage, and the results suggest a new form of treatment for patients with endometriosis.<\/jats:p>","DOI":"10.1136\/bmj.287.6406.1667","type":"journal-article","created":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T11:00:59Z","timestamp":1238670059000},"page":"1667-1669","source":"Crossref","is-referenced-by-count":83,"title":["Intranasal treatment with luteinising hormone releasing hormone agonist in women with endometriosis."],"prefix":"10.1136","volume":"287","author":[{"given":"R W","family":"Shaw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H M","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[1983,12,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/00007611-194812000-00013","article-title":"The use of stilbestrol for endometriosis-preliminary record","volume":"41","author":"Karnaky, K.J.","year":"1948","unstructured":"Karnaky KJ. The use of stilbestrol for endometriosis-preliminary record. South Med J 1948;41:1109-1 1.","journal-title":"South Med J"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0002-9378(58)90384-3","article-title":"The use of progestins in the treatment of endometriosis","volume":"750","author":"Kistner, R.W.","year":"1958","unstructured":"Kistner RW. The use of progestins in the treatment of endometriosis. Am J Obstet Gynecol 1958;750:264-78.","journal-title":"Am J Obstet Gynecol"},{"key":"ref_3","first-page":"197","article-title":"The treatment of endometriosis with danazol","volume":"1","author":"Friedlander, R.L.","year":"1973","unstructured":"Friedlander RL. The treatment of endometriosis with danazol. J Reprod Med 1973;1O:197-9.","journal-title":"J Reprod Med"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/0002-9378(75)90499-8","article-title":"Danazol: an antigonadotropin agent in the treatment of pelvic endometriosis","volume":"123","author":"Laversen, N.H.; Wilson, K.H.; Birnbaum, S.","year":"1975","unstructured":"Laversen NH, Wilson KH, Birnbaum S. Danazol: an antigonadotropin agent in the treatment of pelvic endometriosis. Am J Obstet Gynecol 1975;123:742-7.","journal-title":"Am J Obstet Gynecol"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0010-7824(81)90104-9","article-title":"Influence of the LHRH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control","volume":"23","author":"Schmidt-Gollwitzer, M.; Hardt, W.; Schmidt-Gollwitzer, K.","year":"1981","unstructured":"Schmidt-Gollwitzer M, Hardt W, Schmidt-Gollwitzer K, et al. Influence of the LHRH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control. Contraception 1981; 23:187-95.","journal-title":"Contraception"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2265.1982.tb02638.x","article-title":"Intranasal LHRH agonist treatment for inhibition of ovulation in women: clinical aspects","volume":"17","author":"Bergquist, C.; Nillius, S.J.; Wide, L.","year":"1982","unstructured":"Bergquist C, Nillius SJ, Wide L. Intranasal LHRH agonist treatment for inhibition of ovulation in women: clinical aspects. Clin Endocrinol 1982;17:91-8.","journal-title":"Clin Endocrinol"},{"key":"ref_7","first-page":"109","article-title":"Female contraceptive potential of \"super\" agonists of LHRH as assessed in intra-human primates","volume-title":"as male andfemale contraceptives","author":"Vickery, B.H.","year":"1982","unstructured":"Vickery BH. Female contraceptive potential of \"super\" agonists of LHRH as assessed in intra-human primates: In: Zatuchni G, ed. LHRH peptides as male andfemale contraceptives. Philadelphia: Lippincot, 1982: 109-25."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1210\/endo-112-1-245","article-title":"Effect of treatment for one year with a luteinizing hormonereleasing hormone agonist on ovarian, thyroidal and adrenal function and menstruation in the stumptailed monkey (Macaca arctoides)","volume":"112","author":"Fraser, H.M.","year":"1983","unstructured":"Fraser HM. Effect of treatment for one year with a luteinizing hormonereleasing hormone agonist on ovarian, thyroidal and adrenal function and menstruation in the stumptailed monkey (Macaca arctoides). Endocrinology 1983;112:245-53.","journal-title":"Endocrinology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2265.1982.tb01596.x","article-title":"Fertility after childbirth: infant feeding patterns, basal PRL levels and post partum ovulation","volume":"17","author":"Howie, P.W.; McNeilley, A.S.; Houston, M.J.","year":"1982","unstructured":"Howie PW, McNeilley AS, Houston MJ, et al. Fertility after childbirth: infant feeding patterns, basal PRL levels and post partum ovulation. Clin Endocrinol 1982;17:315-22.","journal-title":"Clin Endocrinol"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1530\/acta.0.1030151","article-title":"Antibody production against an agonist analogue of luteinizing hormone-releasing hormone: evaluation of immunochemical and physiological consequences","volume":"103","author":"Fraser, H.M.; Sandow, J.; Krauss, B.","year":"1983","unstructured":"Fraser HM, Sandow J, Krauss B. Antibody production against an agonist analogue of luteinizing hormone-releasing hormone: evaluation of immunochemical and physiological consequences. Acta Endocrinol 1983;103:151-7.","journal-title":"Acta Endocrinol"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0015-0282(16)42807-4","article-title":"Suggested classification of endometriosis relationship to infertility","volume":"28","author":"Kistner, R.W.; Siegler, A.M.; Behrman, S.J.","year":"1977","unstructured":"Kistner RW, Siegler AM, Behrman SJ. Suggested classification of endometriosis relationship to infertility. Fertil Steril 1977;28:1008-10.","journal-title":"Fertil Steril"},{"key":"ref_12","first-page":"844","article-title":"Gonadotropin-releasing hormone agonist suppresses ovulation, menses, and endometriosis in monkeys: an individualized intermittent regimen. J7 Clin Endocrinol Metab","volume":"56","author":"Werlin, L.B.; Hodgen, G.D.","year":"1983","unstructured":"Werlin LB, Hodgen GD. Gonadotropin-releasing hormone agonist suppresses ovulation, menses, and endometriosis in monkeys: an individualized intermittent regimen. J7 Clin Endocrinol Metab 1983;56:844-8."},{"key":"ref_13","first-page":"1081","article-title":"\"Medical oophorectomy\" using a long-acting GnRH agonist-a possible new approach to the treatment of endometriosis. CJl1in Endocrinol Metab","volume":"54","author":"Meldrum, D.R.; Chang, R.J.; Lu, J.","year":"1982","unstructured":"Meldrum DR, Chang RJ, Lu J, et al. \"Medical oophorectomy\" using a long-acting GnRH agonist-a possible new approach to the treatment of endometriosis. CJl1in Endocrinol Metab 1982;54:1081-3."},{"key":"ref_14","first-page":"376","article-title":"Potential new treatment of endometriosis: reversible inhibition of pituitary ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LHRH) agonist","volume-title":"Fertil Steril","volume":"38","author":"Lemay, A.; Quesnel, G.","year":"1982","unstructured":"Lemay A, Quesnel G. Potential new treatment of endometriosis: reversible inhibition of pituitary ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LHRH) agonist. Fertil Steril 1982;38:376-9."},{"article-title":"Accepted","year":"1983","key":"ref_15","unstructured":"(Accepted 14 September 1983)"},{"key":"ref_16","unstructured":"Phenytoin was first made available for the treatment of epilepsy in 1938. Since then, despite a lack of clinical and scientific evidence, it has been widely believed and taught that anticonvulsants, and in particular phenytoin, cause or aggravate acne.' We report the results of a study of patients with epilepsy who were taking anticonvulsants and were in hospital long term. We set out to ascertain whether acne was more prevalent in patients with epilepsy than in the general population. Seborrhoea is cited as being one of the causative factors in acne,2 and we therefore measured the rate of excretion of sebum in a selected number of the patients. We also studied particularly those patients taking phenytoin as this is the drug most commonly linked with acne.","article-title":"Phenytoin was first made available for the treatment of epilepsy in 1938. Since then, despite a lack of clinical and scientific evidence, it has been widely believed and taught that anticonvulsants, and in particular phenytoin, cause or aggravate acne.' We report the results of a study of patients with epilepsy who were taking anticonvulsants and were in hospital long term. We set out to ascertain whether acne was more prevalent in patients with epilepsy than in the general population. Seborrhoea is cited as being one of the causative factors in acne,2 and we therefore measured the rate of excretion of sebum in a selected number of the patients. We also studied particularly those patients taking phenytoin as this is the drug most commonly linked with acne"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.287.6406.1667","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.287.6406.1667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T23:16:50Z","timestamp":1765322210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.287.6406.1667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983,12,3]]},"references-count":16,"journal-issue":{"issue":"6406","published-online":{"date-parts":[[1983,12,3]]},"published-print":{"date-parts":[[1983,12,3]]}},"alternative-id":["10.1136\/bmj.287.6406.1667"],"URL":"https:\/\/doi.org\/10.1136\/bmj.287.6406.1667","relation":{},"ISSN":["0007-1447","1468-5833"],"issn-type":[{"type":"print","value":"0007-1447"},{"type":"electronic","value":"1468-5833"}],"subject":[],"published":{"date-parts":[[1983,12,3]]}}}